Cargando…

A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy

BACKGROUND: Early intervention for acute severe ulcerative colitis (ASUC) improves outcomes. Outcomes and healthcare costs for an infliximab-first and colectomy-first approach were compared. METHODS: This single-center retrospective cohort study of inpatients with steroid-refractory ASUC who receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasudevan, Abhinav, Arachchi, Asiri, Scanlon, Cian, Greenhalgh, Jarrod, Van Langenberg, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354298/
https://www.ncbi.nlm.nih.gov/pubmed/30728932
http://dx.doi.org/10.1177/2040622319825595
_version_ 1783391154883002368
author Vasudevan, Abhinav
Arachchi, Asiri
Scanlon, Cian
Greenhalgh, Jarrod
Van Langenberg, Daniel R.
author_facet Vasudevan, Abhinav
Arachchi, Asiri
Scanlon, Cian
Greenhalgh, Jarrod
Van Langenberg, Daniel R.
author_sort Vasudevan, Abhinav
collection PubMed
description BACKGROUND: Early intervention for acute severe ulcerative colitis (ASUC) improves outcomes. Outcomes and healthcare costs for an infliximab-first and colectomy-first approach were compared. METHODS: This single-center retrospective cohort study of inpatients with steroid-refractory ASUC who received infliximab 5 mg/kg (1–3 doses without maintenance) or initial colectomy between 2004 and 2014 assessed long-term healthcare utilization and direct costs following infliximab or colectomy, using admission coding data until 31 December 2016. RESULTS: A total of 118 patients received either infliximab (n = 85, 72%) or colectomy (n = 33, 28%) as initial therapy, with 35(41%) patients eventually requiring colectomy post-infliximab (median 213 days, range [6, 3739]). Median follow up was 7 years [0, 14]. Following infliximab for ASUC, 44% of patients then received antitumor necrosis factor maintenance. After ASUC therapy, length of stay and number of admissions did not significantly differ between groups but higher numbers of complications prompting readmission occurred in the colectomy group (median 4 versus 1, p < 0.001). There were no differences in admissions or total length of stay for patients who had received infliximab first then colectomy versus those treated with colectomy first (median 7.0 versus 4.0, 41.5 days versus 29 days, respectively, each p > 0.05). Total costs were lower at 6 months (mean AUD17,662 versus AUD24,852, p = 0.003), yet were similar at 7 years following an infliximab compared with colectomy approach (AUD72,834 versus AUD59,557, p = 0.23). After infliximab, costs were significantly higher at 7 years with biologic rather than immunomodulator-only maintenance therapy (AUD109,365 versus AUD47,842, p < 0.01). CONCLUSIONS: In support of current practice, infliximab salvage in steroid-refractory ASUC achieved reduced short-term healthcare costs compared with initial colectomy, though long-term costs were not significantly different.
format Online
Article
Text
id pubmed-6354298
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-63542982019-02-06 A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy Vasudevan, Abhinav Arachchi, Asiri Scanlon, Cian Greenhalgh, Jarrod Van Langenberg, Daniel R. Ther Adv Chronic Dis Original Research BACKGROUND: Early intervention for acute severe ulcerative colitis (ASUC) improves outcomes. Outcomes and healthcare costs for an infliximab-first and colectomy-first approach were compared. METHODS: This single-center retrospective cohort study of inpatients with steroid-refractory ASUC who received infliximab 5 mg/kg (1–3 doses without maintenance) or initial colectomy between 2004 and 2014 assessed long-term healthcare utilization and direct costs following infliximab or colectomy, using admission coding data until 31 December 2016. RESULTS: A total of 118 patients received either infliximab (n = 85, 72%) or colectomy (n = 33, 28%) as initial therapy, with 35(41%) patients eventually requiring colectomy post-infliximab (median 213 days, range [6, 3739]). Median follow up was 7 years [0, 14]. Following infliximab for ASUC, 44% of patients then received antitumor necrosis factor maintenance. After ASUC therapy, length of stay and number of admissions did not significantly differ between groups but higher numbers of complications prompting readmission occurred in the colectomy group (median 4 versus 1, p < 0.001). There were no differences in admissions or total length of stay for patients who had received infliximab first then colectomy versus those treated with colectomy first (median 7.0 versus 4.0, 41.5 days versus 29 days, respectively, each p > 0.05). Total costs were lower at 6 months (mean AUD17,662 versus AUD24,852, p = 0.003), yet were similar at 7 years following an infliximab compared with colectomy approach (AUD72,834 versus AUD59,557, p = 0.23). After infliximab, costs were significantly higher at 7 years with biologic rather than immunomodulator-only maintenance therapy (AUD109,365 versus AUD47,842, p < 0.01). CONCLUSIONS: In support of current practice, infliximab salvage in steroid-refractory ASUC achieved reduced short-term healthcare costs compared with initial colectomy, though long-term costs were not significantly different. SAGE Publications 2019-01-29 /pmc/articles/PMC6354298/ /pubmed/30728932 http://dx.doi.org/10.1177/2040622319825595 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Vasudevan, Abhinav
Arachchi, Asiri
Scanlon, Cian
Greenhalgh, Jarrod
Van Langenberg, Daniel R.
A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy
title A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy
title_full A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy
title_fullStr A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy
title_full_unstemmed A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy
title_short A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy
title_sort comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354298/
https://www.ncbi.nlm.nih.gov/pubmed/30728932
http://dx.doi.org/10.1177/2040622319825595
work_keys_str_mv AT vasudevanabhinav acomparisonoflongtermhealthcareutilizationandcostsinpatientswithacutesevereulcerativecolitisreceivinginfliximabversusearlycolectomy
AT arachchiasiri acomparisonoflongtermhealthcareutilizationandcostsinpatientswithacutesevereulcerativecolitisreceivinginfliximabversusearlycolectomy
AT scanloncian acomparisonoflongtermhealthcareutilizationandcostsinpatientswithacutesevereulcerativecolitisreceivinginfliximabversusearlycolectomy
AT greenhalghjarrod acomparisonoflongtermhealthcareutilizationandcostsinpatientswithacutesevereulcerativecolitisreceivinginfliximabversusearlycolectomy
AT vanlangenbergdanielr acomparisonoflongtermhealthcareutilizationandcostsinpatientswithacutesevereulcerativecolitisreceivinginfliximabversusearlycolectomy
AT vasudevanabhinav comparisonoflongtermhealthcareutilizationandcostsinpatientswithacutesevereulcerativecolitisreceivinginfliximabversusearlycolectomy
AT arachchiasiri comparisonoflongtermhealthcareutilizationandcostsinpatientswithacutesevereulcerativecolitisreceivinginfliximabversusearlycolectomy
AT scanloncian comparisonoflongtermhealthcareutilizationandcostsinpatientswithacutesevereulcerativecolitisreceivinginfliximabversusearlycolectomy
AT greenhalghjarrod comparisonoflongtermhealthcareutilizationandcostsinpatientswithacutesevereulcerativecolitisreceivinginfliximabversusearlycolectomy
AT vanlangenbergdanielr comparisonoflongtermhealthcareutilizationandcostsinpatientswithacutesevereulcerativecolitisreceivinginfliximabversusearlycolectomy